While the "micro story" with individual companies is good right now, the macro picture isn't so bullish, Joe Duran says. » Read More
By: Dan Mangan
The gunman in the massacre in Las Vegas had at least 12 rifles fitted with a device that allowed him to hire hundreds of rounds per minute. » Read More
By: Jacob Pramuk
Sixty-six percent of voters support stricter gun laws, compared with 31 percent who do not, the Quinnipiac University poll found. » Read More
Toyota's electric-motor magnet cuts the content of rare-earth elements in half, making it potentially cheaper and less vulnerable to shortages.
The products could spark a price war and put pressure on other store-brand profit margins.
Real estate investment trust Kimco Realty is poised to be one beneficiary of Albertsons acquiring Rite Aid.
AT&T's request for the US Justice Department to disclose Trump's views on the company's proposed merger with Time Warner has been denied.
High 401(k) plan fees could shave 10 years or more off your retirement.
The last White House press briefing was a week ago, when Sarah Sanders offered conflicting accounts of the ouster of Rob Porter.
Rising interest rates may not be the culprit many investors think they are, according to a Credit Suisse study.
Rumors that Molycorp may seek bankruptcy protection sent its shares plummeting last week.
President Trump used to boast about forcing pipelines to use U.S. steel, but he has dropped the plan from his stump speech.
The monarch chatted with American Vogue editor Anna Wintour and presented an award recognizing British design excellence.
More accounts of the Internet Research Agency's stranger activities have come forward from former employees.
Investors are spooked that a cooling off of Walmart's online sales could mean the company isn't positioned to fend off Amazon.
The Hollywood couple announced they will march in support of student survivors of the Parkland, Fla. shooting rampage, USA Today reports.
Milo Yiannopoulos is dropping his lawsuit against Simon & Schuster after deciding it was not worth the time or money.
As a record number of people took to the skies in the U.S. last year, the airline industry found customer satisfaction edged lower.
Aimmune Therapeutics' peanut allergy drug met the main goal of a late-stage study, sending shares sharply higher.
Get the best of CNBC in your inbox
Jonathon Morgan, New Knowledge, discusses the return of Russian bots on social media platforms pushing extreme rhetoric around the Florida high school mass shooting.
Steve Odland, Committee of Economic Development president & CEO, discusses CNBC's Andrew Ross Sorkin's New York Times op-ed about banks controlling gun sales.
CNBC's Jackie DeAngelis reports on the quarterly earnings for LendingClub.